Introduction
The systemic inflammatory response syndrome great diversity of SIRS leads to multiple overlapping subgroups of patients unsuitable for statistical com-(SIRS)1 can be initiated by a number of viral, bacterial, protozoal and fungal toxins, including lipoparison. 9 We believe that an ethically acceptable and prepolysaccharides released from the cell walls of Gramnegative bacteria. Studies in animals,2,3,4 human dictable model of SIRS is required to enable the accurate assessment of the potential role of antibodvolunteers5 and patients6 suggest that TNFa is the most important mediator in this syndrome, but that ies directed against a single or multiple10 cytokines. The Jarisch-Herxheimer reaction ( J-HR) which usuother cytokines, including IL-1b, IL-6 and IL-8, are also involved. Despite treatment with antimicrobials ally follows antibiotic treatment of louse-borne relapsing fever (LBRF) meets some of the requireand supportive measures, SIRS continues to have a mortality of up to 60%, and it has been suggested ments of such a model. Clinical manifestations of the reaction are predictable in their timing and that it might best be treated by neutralizing one or more of the mediating cytokines with, for example, nature and closely resemble those of a classical endotoxin reaction.11 Furthermore, Negussie and his specific antibodies.7 The effectiveness of this approach remains unproven, because animal models colleagues showed that the J-HR which followed penicillin therapy and the resultant clearance of may be inappropriate,8 while in clinical studies the spirochaetes from the circulation was associated with Blood samples (10 ml) were taken into sterile endotoxin-free lithium heparin tubes immediately before a several-fold rise in circulating levels of TNFa, IL-6 and IL-8. 12 starting the first infusion (−0.5 h), at the time of the penicillin injection (0 h) and after a further 1, 1.5, The present double-blind, placebo-controlled study was designed to determine whether ovine 2, 4, 8 and 24 h. The samples were separated by centrifugation immediately and the plasma was kept antibody fragments (Fab) directed against TNFa would suppress circulating cytokine levels and hence at −20°C until assayed at St Bartholomew's Hospital for TNFa, IL-1b, IL-6 and IL-8. Commercial kits for the J-HR-since this might be relevant to the treatment of SIRS and other clinical conditions in which IFNc and the two soluble TNFa receptors, sTNF-R1 (p55) and sTNF-R2 (p75) were generously donated, high levels of circulating TNFa have been found. This paper relates primarily to plasma cytokine levels, which enabled samples from nine of the patients (six from the control and three from the treated groups) and for reasons of brevity the clinical findings are reported in detail elsewhere. 13 to be assayed. Thin blood smears were prepared at the same time intervals on glass microscope slides, stained using Wright's stain and examined by light microscopy by an independent observer for the Methods presence and number of B. recurrentis. Baseline
Patients measurements of rectal temperature (using a rectal probe), of blood pressure (by an automatic sphygmo-A total of 49 patients, (46 males and 3 females), manometer), and of the respiratory and pulse rates were recruited from hospitals and health clinics in were recorded at frequent intervals throughout. The Addis Ababa. They were between 12 and 60 years clinical severity of the J-HR was graded as none (no old with no clinical evidence of other diseases. All shivering); mild (shivering); moderate (intermittent gave informed consent. The diagnosis of LBRF was rigors) or severe (severe sustained rigors) by a clinibased on clinical suspicion confirmed by finding cian who, like the rest of the clinical team, was Borrelia recurrentis spirochaetes in their peripheral blinded to the patient's treatment. blood film stained with Wright's stain. Clinical history and examination were recorded on standard proformas, and patients lay supine in bed throughout the Cytokine assays study with an intravenous cannula inserted into both arms for blood sampling and drug administration.
These were all performed by one person (REC) using commercial immunoassay kits (Medgenix, Belgium) according to the manufacturer's instructions. Each Antibody kit is based on several monoclonal antibodies dirSheep were immunized with recombinant human ected against different epitopes on the macroTNFa in Freund's adjuvant and the antibodies were molecule to be measured, as a means of reducing precipitated with sodium sulphate and cleaved with hyperspecificity and incubation times and of increaspapain to give Fab and Fc. These were supplied by ing sensitivity. Therapeutic Antibodies Inc. as lyophilized ovine polyclonal anti-TNFa Fab. Non-specific antibodies Immunoradiometric Assay (IRMA) for TNFa from a donor flock were similarly processed and Standards or samples (200ml) were added to plastic supplied as ovine control Fab. The infusions were tubes coated with several monoclonal antibodies prepared by someone not involved in the care or directed against different epitopes on TNFa (the assessment of the patients, who dissolved the concapture antibodies), followed immediately by monotents of 4×1.5 g vials of lyophilized anti-TNFa or clonal antibodies labelled with 125I (the signal anticontrol Fab in 100 ml of 0.9% saline. bodies). Standards are provided in human serum with levels between 0-5000 ng/l, and one ng of the
Protocol and clinical measures
Medgenix standard is equivalent to 32 U of the International Reference Standard (NIBSC 87/650). Patients were randomized for treatment with antiTNFa Fab (20 patients), control Fab (19 patients) or After 16 to 24 h at room temperature, the contents of the tubes were aspirated (or decanted) to waste 0.9% saline alone (10 patients). After stabilization of core temperature (i.e. ±0.5°C for 30 min), the test and the tubes were washed carefully and counted using a Hydrogramma 16 (Innotron). The assay infusion was given over a 30-min period. A curative dose of procaine penicillin (600 000 units) was then measures total TNFa (i.e. free TNFa as well as that bound to natural soluble receptors).14 The assay has administered by deep intramuscular injection into the anterior thigh, and an infusion of 0.9% saline a minimum detectable level (MDL) of 5 ng/l and serum or plasma TNFa levels in normal subjects was continued at a rate of 1 L per 8 h for 24 h. range from less than 5 to about 20 ng/l with a mean IEMA for sTNF-R2
This assay is virtually the same as that for sTNF-R1 with sTNF-R2 standards (in bovine serum) ranging
IRMA for IL-1b
between 0 and 142 mg/l. There was no interference in the assay due to sTNF-R1 and TNF, at 1500 mg/l This assay is virtually identical to the TNFa assay.
and 400 mg/l, respectively. The MDL was 100 ng/l Standards range from 0 to 5000 ng/l and each ng of and serum levels in 117 normal subjects ranged from standard is equivalent to 200 U of an International 1.91 to 8.51 mg/l with a mean of 4.17 mg/l. Reference Preparation (NIBSC 86/552). The MDL is 5 ng/l and values are usually undetectable in plasma or serum from normal subjects but may, on occasion,
Statistical analysis
be as high as 15 ng/l.
The Mann-Whitney U test was used to analyse the differences in admission and peak cytokine concen-
IRMA for IL-6
trations. For comparison with the data obtained in the group receiving anti-TNFa Fab, the saline control This assay is similar to the above except that it was and non-specific Fab groups were combined for done in two steps to help avoid a high-dose hook analysis, as there was no significant differences effect. Samples and standards (200 ml) were incubbetween their clinical findings and cytokine levels. ated in the antibody-coated tubes for 16-20 h and then aspirated (or decanted) to waste before addition of 200 ml 125I-labelled monoclonal antibodies.
Ethical approval
Standards range between 0 and 5000 ng/l and 1 ng Ethical approval for the study was given by the is equivalent to 3.5 U of a Reference Preparation
Research Ethics Committee, Faculty of Medicine, (NIBSC 88/514). Levels of IL-6 in 157 normal plasma Addis Ababa University. samples were below the levels of detection (6 ng/l) in 39 and ranged from 6 to 31 ng/l in the remainder.
Results

IRMA for IFNc
There were no significant differences in either the This assay is based on the same principle as the clinical or plasma cytokine findings for patients TNFa assay. Standards range from 0 to 90 IU/ml and receiving saline or control Fab. The two have, one IU/ml of the Medgenix standard is stated by the therefore, been combined to provide what will be manufacturer to be equivalent to 1 IU/ml NIH Gg referred to as the control group (comprising 29 23-901-530 standard. The assay has an MDL of 0.2 patients). The remaining 20 patients who received IU/ml and a mean value of 0.55±0.14 has been ovine anti-TNFa Fab are referred to as the test group. reported in 20 normal controls.
Clinical findings
Immunoenzymometric Assay (IEMA) for IL-8
In this paper, for simplicity, the patients are only The general format differed in that the capture graded according to the severity of their J-HR as monoclonal antibodies were used to coat the walls defined earlier. Of the 29 controls, three had no of microtitre plates while the signal antibodies were reaction, while 12, 11 and three experienced mild, labelled with horseradish peroxidase. The resultant moderate and severe J-HRs, respectively. In contrast, assay was very sensitive, with a MDL of 0.7 ng/l, 10 of the test group had no reaction and the other and used standards ranging between 0 and 750 ng/l, 10 only mild J-HR. Both the incidence and severity where 1 ng of standard is equivalent to 0.14 U of of the J-HR in the two groups differed significantly the International Reference Standard (NIBSC 89/520).
( p<0.01 and <0.005, respectively) with the FabNormal values range from <8 to 47 ng/l. receiving patients experiencing less severe reactions. Systolic blood pressure, pulse rate and temperature
IEMA for sTNF-R1
increased less in the test group compared with the This has the same format as the IL-8 assay. Standards control group.13 were provided in bovine serum with concentrations between 0 and 77 mg/l. sTNF-R2 and TNFa, at
Basal cytokine levels concentrations of 1500 mg/l and 400 mg/l, respectively, did not cross-react with sTNF-R1 in the assay.
All 49 patients had cytokine assays performed on at least one basal plasma sample collected before The MDL was 50 ng/l, and levels in 129 normal sera ranged from 0.3 mg/l to 2.9 mg/l with a mean of treatment began. There was no significant difference in these basal cytokine levels between the control 1.2 mg/l. Basal levels of TNFa and IL-6 were markedly above the quoted upper limit of normal; there was no significant difference between basal cytokine levels in the control and test group; 50% of IL-8 levels were raised and IL-1b levels were mostly unaffected. Nine patients had IFNc and soluble-receptor assays performed on two basal samples; median admission levels for s-TNF-R1 and sTNF-R2 were 6 and 29 times the upper limit of normal, respectively, and IFNc was normal.
and test groups. The results are summarized in kines. Data on the exact time that cytokine levels Table 1 . Every sample tested had TNFa and IL-6 started to rise are not accurate, because insufficient levels markedly above the upper limit of the normal blood samples were collected at the appropriate range, with median values more than 10 and 60 times. Plasma levels were raised significantly above times higher, respectively. IL-8 levels were elevated baseline for TNFa ( p<0.0001) and IL-6 ( p=0.0001) in about 50% of samples while baseline values of by 1.5 h, for IL-8 by 2 h ( p=0.0003) and for IL-1b IL-1b appeared unaffected. In general, basal admisat 4 h ( p=0.0002). Median levels for all four cytosion levels remained stable or fluctuated only slightly kines continued to rise until a peak concentration between −0.5 and 0 h. was reached at 4 h, after which levels started to fall Nine of the patients also had IFNc and solubleand were below admission levels at 24 h. TNFa, receptor assays performed on two basal samples.
IL-6 and IL-8 were detected throughout the study The median of admission levels for IFNc was normal period (−0.5 to 24 h) in every patient, including and those for sTNF-R1 and sTNF-R2 were markedly two who did not have clinical evidence of a J-HR. raised, with values 6 and more than 29 times the There was no obvious relationship (although the upper limit of normal, respectively (Table 1) .
relative sample size was small) between plasma peak cytokine levels and the severity of the J-HR as shown
Cytokine profiles during the J-HR for each patient in the control group (Figure 2 ). There were additional assays in six controls. IFNc
Control patients
plasma concentration levels remained normal Figure 1 shows a typical response in a patient who throughout the study period. sTNF-R1 and sTNF-R2 received a saline infusion before penicillin and levels were markedly elevated throughout, and no developed a severe J-HR. Almost immediately after obvious rise nor fall in levels, was apparent. penicillin treatment, the spirochaete count started to fall and by 8 h spirochaetes were undetectable in
Control group (n=29) vs. test group (n=20)
the peripheral blood film (in the other patients,
The typical rise to a peak and then fall of circulating spirochaete clearance was unaffected by the test Fab cytokine levels seen in the control group (Figure 3a ) and was the same in both groups13). After a delay was not detected in the test group (Figure 3b) . Thus, of about 1 h a rise in TNFa and IL-6 levels was 'measured' plasma levels of TNFa fell dramatically, detected, followed by IL-8 (at 1.5 h) and IL-1b during the 30-min infusion of anti-TNFa from a between 2 and 3 h. The increase in plasma cytokine median baseline level at −0.5 of 225 ng/l to 3 ng/l levels coincided with or preceded clinical signs of at 0 h and remained low throughout the study period. J-HR, but peaked after the rigors had subsided. In
There was no significant change in the median this patient, IL-1b and IL-8 levels had returned to circulating cytokine levels from baseline for IL-8 and baseline by 24 h, and TNFa and IL-6 were lower.
IL-1b throughout the study period, but IL-6 levels The median plasma levels and percentiles rose from a median baseline of 2.8 mg/l to 6.5 mg/l (10th-90th) for TNFa, IL-1b, IL-6 and IL-8 over time ( p=0.001) at 2 h. Cytokine levels for this group are for the 29 control patients are listed in Table 2 . ILlisted in Table 2 . Median peak levels occurred at the 1b was undetected in 8/29 patients throughout the same time (4 h) as in the control group, but were study period, and levels were much lower and restricted to a narrower range than the other cytosignificantly lower for TNFa, IL-6 and IL-8, and are Figure 1 . Typical response in a patient receiving a control saline infusion 30 min before penicillin. After penicillin, spirochaetes fell abruptly, and after about 1 h circulating levels of TNFa, IL-6, IL-8, and IL-1b started to rise, and peaked at 4 h. This patient experienced sustained rigors which occurred as cytokine levels were increasing and subsided before peak levels were achieved. compared in Table 3 . The J-HR occurred in 50% of anti-TNFa Fab. Clearly the latter interfered with the assay. the test group and was mild.
In additional assays, IFNc and sTNF-R1 and
On TNFa standards
sTNF-R2 levels in three patients receiving test Fab were similar to those in the six controls. The IRMA for TNFa is based on the use of capture monoclonal antibodies adsorbed to the assay tubes, and signal antibodies labelled with 125I which are
In vitro studies of the effect of anti-TNFa added to the tubes immediately after the standards Fab on the measurement of TNFa (or sample). The more TNFa present in a standard, the more will bind to the capture antibodies and
On endogenous TNFa
provide a link so that the amount of radioactivity Duplicate aliquots of plasma were prepared from the (cpm) in the tube after washing is directly related to series of samples collected from a control patient the amount of TNFa in the sample. Each TNFa who had received only a saline infusion and was standard provided in the kit was preincubated with known to have had a marked rise in TNFa following saline, Fab control or specific anti-TNFa Fab and his penicillin injection. One series of aliquots was then assayed in the usual way. The maximal amount preincubated with control Fab and the other with of TNFa (i.e. with the highest cpm) was detected in anti-TNFa Fab in an amount calculated to be similar the standards preincubated with saline or control to that encountered in vivo in test subjects. The Fab, while TNFa was almost undetectable in the samples were then assayed in the usual way. As standards containing anti-TNFa. Finally, a high TNFa expected, TNFa levels increased markedly from a standard was preincubated with doubling dilutions mean basal level of 780 ng/l to a peak of nearly of control or anti-TNFa Fab prior to assay. As shown 5000 ng/l in the samples containing control Fab, but in Figure 4 , there was a gradual increase in the were dramatically lower with a mean basal level of amount of TNFa apparently being measured as the amount of anti-TNFa was reduced. 50 ng/l and a peak of 160 ng/l in samples containing In the combined control group (n=29), median TNFa and IL-6 levels were raised significantly above baseline by 1.5 h, for IL-8 by 2 h and IL-1b by 4 h. Median peak levels occurred at 4 h for all of these cytokines. * Range of 10th-90th percentiles.
study, but admission plasma levels were normal, and Discussion only 12 of the 29 control subjects (41%) showed a Negussie and his colleagues were the first to report rise following penicillin injection and then only of a that severe J-HRs, which occurred in 14 of their 17 minor degree. These findings accord with those of patients (82%) with LBRF treated with penicillin, are Cannon and his colleagues16 who used a radioassociated with, and probably caused by, a transient, immunoassay to determine plasma levels of IL-1b in marked rise in plasma levels of TNFa followed by patients with septic shock and in normal subjects IL-6 and IL-8. The plasma levels of these cytokines infused with endotoxin. increased between four-and ten-fold compared to Great care must be taken in interpreting assay admission, as determined by bioassay (for TNFa and results, since various factors can influence different IL-6) or an immunoassay (for IL-8). The three patients types of assay to different degrees. For example, the who did not develop a typical J-HR showed no two soluble receptors to TNFa found in the circulacytokine response. We have, in general, confirmed tion (sTNF-R1 and sTNF-R2) are known to be raised these findings in a larger control group. Although it markedly in septic shock, and were present in is not possible to compare actual cytokine levels extremely high concentrations in the nine patients directly, because of differences in the assays and whose samples were assayed in this study. standards used, the profile of the cytokine release in Engelberts14 and his colleagues have shown that the two studies was remarkably similar. Median such levels had profound and differing effects on a values for TNFa, IL-6 and IL-8 at each time-point for WEHI 164 bioassay, an enzymoimmunoassay and both studies had increased significantly above basean IRMA for TNFa. However, the TNFa IRMA used line by 1.5 h for TNFa and IL-6, and by 2 h, IL-8 in the present study was chosen because the results showed a four-fold increase. Each cytokine had obtained are not influenced by the presence of peaked at 4 h, when TNFa, IL-6 and IL-8 had soluble receptors. increased 8-, 18-and 17-fold over baseline, respectOne reason for undertaking the present study is ively. However, the three control patients in our that the J-HR that complicates antibiotic treatment study who did not develop symptoms of a J-HR of LBRF resembles other forms of SIRS in its clinical showed a typical cytokine response, which is in features and cytokine changes. Also, the J-HR has agreement with Cuevas and colleagues.15 IFNc levels the advantage of predictability, which contrasts with were normal throughout the study and there was no previous clinical trials in SIRS, where it is unlikely relationship to the J-HR.
IL-1b assays were also performed in the present that patients would be diagnosed and available for antibodies have been directed against lipopolysaccharides (LPS).17 This lack of success may reflect the heterogeneous nature of septic shock. Alternatively, as we have suggested,18 greater care may need to be taken with the selection of monoclonal antibodies suitable for use in SIRS, and this We have used Fab prepared from polyclonal
There was no obvious relationship between peak plasma antibodies obtained from sheep immunized with cytokine levels and the severity of the reaction, but the rhTNFa for use in the present double-blind placeborelative sample size was small.
controlled trial. Nature invariably mounts a polyclonal response to antigens and, in our experience, such antibodies are usually more effective clinically treatment before the onset of their inflammatory response. Recent experience with the use of specific and require less rigorous selection than their monoclonal counterparts.18 It was hoped that Fab, with monoclonal antibodies for the treatment of septic shock has been disappointing, especially when such their much more rapid rate and larger volume of Median peak levels for TNFa, IL-6, IL-8 and IL-1b occurred at the same time (4 h) in both groups but were significantly lower in patients given anti-TNFa Fab. NS, not significant. *Apparent low levels of TNFa in the test group may be due to interference by the anti-TNFa Fab in the assay.
operates largely in the interstitial rather than the vascular compartment of the extracellular fluid volume. This is, as far as we are aware, the first occasion in which a polyclonal product has been used clinically in a large group of patients with SIRS. Ovine anti-TNFa Fab produced a rapid and profound reduction in 'measured' plasma levels of TNFa which had approached baseline by the end of the 30-min infusion, and remained low throughout the rest of the study. A series of in vitro studies indicated that the polyclonal Fab had, as would be expected, bound to most, or all, of the surface epitopes in TNFa. As a result, neither the capture nor the signal antibodies provided in the immunoradiometric kit could bind to the endogenous TNFa whose disappearance from the circulation was, therefore, probably apparent rather than real. The rate of clearance of circulating Fab-TNFa complexes has not been studied; however, their rapid clearance may be another reason for the apparently low TNFa levels. There is substantial evidence that the antiTNFa Fab also suppressed the biological activity of the endogenous TNFa. Thus, both the incidence and severity of the clinical manifestations of the J-HR were less than in the control group, and circulating levels of IL-6 and IL-8 (but not of IL-1b) were reduced significantly. The changes in interleukin antibody against TNFa abolished plasma TNFa bioactivity and considerably reduced the IL-6 detected in plasma. Macromolecules such as TNFa distribution than intact immunoglobulins, might offer are thought to exert their biological effects by means advantages when used in an attempt to block the of an active site(s) which binds to, and activate, specific cell-wall receptors. The most likely mechanbiological effects of TNFa. This cytokine probably
